WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	76.25B +58.7%
Revenue (ttm)	6.61B +46.7%
Net Income	1.65B +38.4%
EPS	1.25 +34.9%
Shares Out	1.26B
PE Ratio	48.54
Forward PE	32.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,807,500
Average Volume	5,115,895
Open	60.35
Previous Close	60.35
Day's Range	60.00 - 61.35
52-Week Range	30.45 - 85.50
Beta	-0.78
RSI	50.48
Earnings Date	Mar 23, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,662
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.

Financial numbers in CNY